Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620800 · ClinicalTrials.gov registry record · Phase 1
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
A Phase 1 study of Metastatic Pancreas Adenocarcinoma, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT02620800: Completed Phase 1 study of Metastatic Pancreas Adenocarcinoma, sponsored by Celgene.
NCT02620800 is a Phase 1 study of Metastatic Pancreas Adenocarcinoma that has completed, run by Celgene. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02620800, a Phase 1 study of Metastatic Pancreas Adenocarcinoma, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.
Primary Outcome
• Any toxicity starting during the first 28 days of treatment and requiring 14 days or more of treatment interruption • Grade 3 or 4 neutropenia associated with fever \> 38.5°C • Grade 3 anemia requiring a transfusion • Any Grade 4 hematological toxicity lasting \> 7 days • Grade 4 thrombocytopenia or a Grade 3 or 4 thrombocytopenia associated with clinically significant bleeding • Grade 3 or 4 non-hematological toxicity with the exception of fatigue, due to any of the study drugs and unresponsi
Conditions Studied
Interventions
- DRUG nab-paclitaxel
- DRUG bevacizumab
- DRUG oxaliplatin
- DRUG 5FU
- DRUG calcium leucovorin
Study Locations (7)
Michigan
- University of Michigan - Ann Arbor
- Karmanos Cancer Center Wayne State University - Detroit
Illinois
- Northwestern University - Chicago
Massachusetts
- Tufts - New England Medical Center - Boston
New York
- Cornell University Weill Medical College - New York
South Carolina
- Gibbs Cancer Center and Research Institute - Spartanburg
Washington
- Virginia Mason Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-01-18 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 1 |
What the finished NCT02620800 record still lists
NCT02620800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Metastatic Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which nab-paclitaxel is the first listed.
NCT02620800 lists 7 locations in 6 states (Michigan, Illinois, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT02620800 about?
NCT02620800 is a clinical study titled "Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer". The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.
What is the current status of trial NCT02620800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2016-01-18. Estimated completion is 2018-10-29.
What conditions does trial NCT02620800 study?
This clinical trial studies the following conditions: Metastatic Pancreas Adenocarcinoma.
What interventions are being tested in trial NCT02620800?
The interventions under investigation include: nab-paclitaxel (DRUG), bevacizumab (DRUG), oxaliplatin (DRUG), 5FU (DRUG), calcium leucovorin (DRUG).
Who is sponsoring clinical trial NCT02620800?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02620800 being conducted?
This trial has 7 study locations across Illinois, Massachusetts, Michigan, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02620800's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI